New RSV shots slash baby hospitalizations? study digs into Real-World data
NCT ID NCT07164430
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study looked at whether new RSV prevention medicines given to infants or pregnant women reduced hospitalizations for RSV in children under 2. Researchers analyzed health records from over 2,700 children in the Australian Capital Territory. The goal was to see if the 2025 prevention program made a difference in RSV-related hospital stays.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that RSV prevention programs reduce hospitalizations in young children, guiding future public health policies.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other regions or populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Canberra Hospital
Garran, Australian Capital Territory, 2605, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older adults from RSV?
- One shot, two viruses: could a combined vaccine shield seniors from RSV and HMPV?
- RSV shot uptake under the microscope: how many german babies get protected?
- Double defense: new mRNA vaccine targets two lung viruses in seniors
- New mRNA vaccine aims to shield seniors from RSV
- New mRNA vaccine candidates for RSV enter human testing